Pfizer Inc. will stop developing an obesity pill that has been closely watched by investors, a severe blow in its efforts to compete with blockbuster weight-loss shots from Novo Nordisk A/S and Eli L… [read more]
Pfizer Abandons Obesity Pill After Liver Injury in Setback – Bloomberg.com
Date:
More like thisRelated
Intel to Sell 51% Altera Stake to Silver Lake Amid Cost Cuts – Bloomberg.com
Intel Corp. has agreed to sell a 51% stake...
LVMH Sales Fall as Shoppers Curb Spending on Louis Vuitton Bags – Bloomberg.com
LVMH sales fell more than expected in the first...
Gold Slips From Record as Trump Tariff Agenda Stays in Spotlight – Bloomberg.com
Gold climbed to a record as markets weighed the...
Dollar’s Losing Run Shows Wall Street Angst With Tariff U-Turns – Bloomberg.com
Worries over global trade dragged the dollar to a...